The blaugrana team could reinforce very well for the next season with this player, who would make a qualitative leap by ...

SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...

According to the latest information of Football Insider, Manchester City have now set their sights on signing Paris ...

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial ...

Photo by MANAURE QUINTERO/AFP via Getty ImagesBarcelona now return to La Liga action today as they conclude the recent ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...